Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

488 ROSUVASTATIN
Reactions
Skin
Peripheral edema (>2%)
Pruritus (>1%)
Rash (sic) (>2%)
Other
Abdominal pain (>2%)
Cough (>2%)
Infections
Myalgia/Myositis/Myopathy/Myotoxicity (2.8%)
(2007): Dedhia V+, J Assoc Physicians India (India) 55, 152 (with
fenofibrate)
(2007): Kasliwal R+, Drug Saf 30(2), 157
(2006): Glueck CJ+, Clin Ther 28(6), 933 (1 case)
(2005): Samman A+, J Heart Lung Transplant 24(8), 1008
(2004): Davidson MH, Expert Opin Drug Saf 3(6), 547
(2004): Shepherd J+, Am J Cardiol 94(7), 882
Nephrotoxicity
(2005): Alsheikh-Ali AA+, Circulation 111(23), 3051
(2004): Prescrire Int 13(72), 132
Pain (>2%)
Rhabdomyolysis
(2007): Prescrire Int 16(88), 68
(2005): Alsheikh-Ali AA+, Circulation 111(23), 3051
(2005): Blumenthal H, Beachwood, OH (personal
communication)
(2005): Ireland JH+, AnnInternMed142(11), 949 (with
fenofibrate)
(2004): Davidson MH, Expert Opin Drug Saf 3(6), 547
(2004): Wooltorton E, CMAJ 171(2), 129
ROTAVIRUS VACCINE
Trade names: Rotarix* (GSK); RotaTeq* (Merck)
Indications: Prevention of rotavirus gastroenteritis
Half-life: N/A
Clinically important, potentially hazardous interactions
with: N/A
*Note: Rotarix origin is monovalent human live attenuated, RotaTeq
origin is pentavalent bovine live. Only currently licensed forms of the
vaccine are considered here
Reactions
Skin
Dermatitis
Rash (sic)
Other
Abdominal pain
(2006): Vesikari T+, Vaccine 24(22), 4821
Cough
Fever
(2007): Block SL+, Pediatrics 119(1), 11
(2006): Bhandari N+, Vaccine 24(31-3), 5817
(2006): Vesikari T+, Pediatr Infect Dis J 25(2), 118
Myalgia/Myositis/Myopathy/Myotoxicity
Upper respiratory infection
ROTIGOTINE
Trade name: Neupro (Schwarz)
Indications: Parkinsonism
Category: Dopamine receptor agonist
Half-life: 5–7 hours
Clinically important, potentially hazardous interactions
with: N/A
Reactions
Skin
Allergic reactions (sic)
Diaphoresis
Exanthems
Peripheral edema
Pruritus
Purpura
Rash (sic) (2%)
Mucosal
Sialorrhea
Xerostomia
Eyes
Photopsia
Visual disturbances (3%)
Visual hallucinations (2%)
(2001): Metman LV+, Clin Neuropharmacol 24(3), 163
Other
Anorexia (3%)
Application-site dermatitis (contact)
Application-site pruritus
(2007): LeWitt PA+, Neurology 68(16), 1262
Application-site reactions (37%)
(2007): LeWitt PA+, Neurology 68(16), 1262
(2007): Splinter MY, Ann Pharmacother 41(2), 285
(2007): Watts RL+, Neurology 68(4), 272 (44%)
(2003): The Parkinson Study Group, Arch Neurol 60(12), 1721
Fever
Weight gain
ROXATIDINE
Trade name: Roxit (Noristan)
Indications: Gastric and duodenal ulcers
Category: Histamine H2 receptor antagonist
Half-life: 5–6 hours
Clinically important, potentially hazardous interactions
with: None
Reactions
Skin
Erythema multiforme
(2000): Horiuchi Y, JDermatol27(5), 352
Erythroderma
(2005): Igawa K+, Clin Exp Dermatol 30(3), 304
Lichenoid eruption
(2002): Greve B+, Lasers Surg Med 31(1), 23
(1996): Horiuchi Y+, JDermatol23, 510
Pruritus
Rash (sic)